News

A study linked abnormalities in cholesterol metabolism and elevated inflammatory markers to more severe disability in people with progressive forms of multiple sclerosis (MS). “Our results demonstrate marked alterations in metabolic, inflammatory, nutritional, and [brain cell] biomarker networks in Severe [progressive MS], and that disrupted cholesterol metabolism and chronic inflammation…

An educational program aimed at empowering the whole family may help improve mental health for people with multiple sclerosis (MS), according to data from a clinical trial. Results also indicate that the program can help MS patients take more steps to proactively manage their own health, emphasizing the importance…

An MRI technique known as APART-QSM may help researchers track signs of repair to the myelin sheath, which is damaged in people with multiple sclerosis (MS), according to a study from China. Researchers found that increases in a myelin-sensitive MRI measurement within MS lesions were significantly associated…

In the large, late-stage clinical trials that led to the approval of the multiple sclerosis (MS) drug Ocrevus (ocrelizumab), participants with relapsing forms of MS who were initially assigned to — and remained on the infusion therapy for as long as 10 years — had less disability progression…

A low-fat diet may help reduce fatigue in multiple sclerosis (MS) by altering how the body processes lipids, or fats, and amino acids, which serve as the building blocks of proteins, a small study by U.S. researchers suggests. These scientists analyzed data from a small clinical trial involving adults…

Nearly 15% of people with multiple sclerosis (MS) declined free cognitive testing offered at a specialized clinic in Canada, a new study found. Those with progressive MS, anxiety-related disorders, or no reported concerns about their thinking and memory were more likely to decline testing. This could leave…

Workplace exposure to petroleum-based lubricants is linked to higher odds of multiple sclerosis (MS), a new study in Sweden suggests. The association was particularly strong among current smokers and people with certain genetic risk factors. Researchers found that people who reported working with products such as engine oil, concrete…

People with multiple sclerosis (MS) may be able to enjoy ocean sailing as a way to stay active, a small study found, with participants showing no measurable decline in physical or cognitive function after a 10-day expedition. All participants completed the planned sailing activities, although two-thirds experienced some degree…

People with multiple sclerosis (MS) who report engaging in a lot of physical activity tend to have better quality of life and less walking-related disability, regardless of how long ago they were diagnosed, a new study found. The associations between physical activity and several quality-of-life measures were generally stronger…

The first participant has been dosed in a Phase 1/2a clinical trial testing PRO-1562, an experimental oral treatment designed to repair myelin, the protective sheath around nerve fibers that is damaged in people with multiple sclerosis (MS). Developed by Progentos Therapeutics, PRO-1562 aims to…

Adhering to diets that exclude gluten may lead to improvements in fatigue, quality of life, and some measures of disability in people with multiple sclerosis (MS), but it remains unclear whether these benefits stem from avoiding gluten itself or other dietary changes, a review of six studies found. Overall, the…

Children and teenagers in Canada with relapsing-remitting multiple sclerosis (RRMS) now have a second treatment option following Health Canada’s approval of the infusion therapy Ocrevus (ocrelizumab). The regulatory decision extends the use of Ocrevus to patients 10 and older. Previously authorized in Canada only for adults, Ocrevus joins…

A lower dose of the experimental therapy foralumab significantly reduced a marker of brain inflammation in people with nonactive secondary progressive multiple sclerosis (SPMS), according to top-line results from a Phase 2 clinical trial. The 12-week study, called INFORM-MS (NCT06292923), met both its main goals.

The experimental oral therapy remibrutinib significantly reduced relapse rates and brain lesion activity more than the approved therapy Aubagio (teriflunomide) in two Phase 3 clinical trials of people with relapsing forms of multiple sclerosis (MS). The trials, REMODEL-1 (NCT05147220) and REMODEL-2 (NCT05156281), compared remibrutinib with…

Treatment with rituximab, an anti-CD20 therapy that is used off label for multiple sclerosis (MS), may be associated with a significantly higher risk of developing inflammatory bowel disease (IBD), particularly Crohn’s disease, a large study in Sweden found. After accounting for patient differences, researchers found the risk was…

Greater physical disability is associated with poorer cognitive performance in people with multiple sclerosis (MS), particularly in those with more advanced disability, according to a large review and meta-analysis. However, cognitive difficulties may also occur in patients with mild physical impairment, and go undetected by conventional disability assessments. “Cognitive…

In a European study of people newly diagnosed with multiple sclerosis (MS), B-cell-depleting treatments were linked to fewer relapses and greater reductions in brain lesion volume over two years compared with oral treatments. However, changes in disability scores were similar across treatment groups.

Physical activity programs led by healthcare professionals appear acceptable and feasible for adults with multiple sclerosis (MS), a review found. However, more research is needed to determine whether these programs can be successfully used in everyday clinical care. The findings were published in the study, “The implementability of…

Most people with relapsing or progressive forms of multiple sclerosis (MS) had stable or improved disability scores, along with signs of reduced disease activity, after receiving a single infusion of the experimental CAR T-cell therapy zolacabtagene autoleucel (zola-cel). That’s according to interim results from a Phase 1 clinical trial,…

Fewer people with multiple sclerosis (MS) are willing to receive recommended routine vaccines today than before the COVID-19 pandemic, even as neurologists and family doctors talk with them more frequently about immunization, a new study in Germany has found. While vaccination records showed improved coverage for several vaccines, researchers…

Most people with progressive forms of multiple sclerosis (MS) had stable or improved disability scores after receiving the experimental CAR T-cell therapy azercabtagene zapreleucel (azer-cel) in a small Phase 1 clinical trial. TG Therapeutics, which is developing azer-cel under a licensing agreement with its previous developer, Precision…

Early treatment with the experimental oral therapy vidofludimus calcium (IMU-838) may lead to less long-term disability in people with progressive forms of multiple sclerosis (MS), according to new data from the CALLIPER Phase 2 trial and its extension. Immunic, the company developing vidofludimus calcium, presented the findings…

Genentech’s experimental oral therapy fenebrutinib may help control the chronic inflammation in the brain associated with disability progression in both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). That’s according to new analyses of data from three ongoing Phase 3 trials, in which…

About four out of 10 people with multiple sclerosis (MS) in Thailand were found to be either at risk of malnutrition or already malnourished, which appear to be associated with more severe disability, a single-center study shows. Data also showed that a significant proportion of people with two related…

When Christina Applegate was diagnosed with multiple sclerosis (MS) in 2021, she finally had an explanation for the symptoms that had been disrupting her life. The diagnosis also gave her a community where she could share her experiences, find support, and help others facing the same challenges. Now,…

In people with multiple sclerosis (MS), pain is associated with more reported difficulties with thinking and memory, but does not predict how patients perform in objective cognition tests, according to a recent study. Mental health issues, along with pain and fatigue, were associated with greater perceived cognitive problems. “Given…

Small changes in the gene that provides instructions for making the vitamin D receptor (VDR) protein were not individually associated with the risk of multiple sclerosis (MS), but certain variants were linked to motor symptoms and lesions in the upper spinal cord, a new study found. “In summary, this…

Vitamin D and curcumin, a compound found in turmeric, reduced the proportions of certain inflammation-related immune cells in laboratory experiments using blood samples from people with relapsing-remitting multiple sclerosis (RRMS), a study has found. The combination had a greater effect on certain immune cell populations than either compound alone,…

Some paramagnetic rim lesions (PRLs) — MRI findings linked to chronic inflammation — disappeared in the brains of adults with multiple sclerosis (MS) after they underwent an autologous hematopoietic stem cell transplant (aHSCT), a small study found. No new PRLs appeared during follow-up. The findings contrast with an earlier…

A systematic review of clinical studies found no clear evidence that melatonin supplements reduce relapses, disability progression, or new MRI-detected disease activity in people with multiple sclerosis (MS). Some small studies suggested melatonin may improve sleep, fatigue, pain, physical and cognitive function, and mood, but the findings were inconsistent.